rs6954668 — SFRP5 SFRP5 Wnt5a inhibitor variant

SFRP5 — The Adipose Anti-Inflammatory That Holds Wnt5a in Check

Your adipose tissue is more than a fuel depot — it is an active endocrine organ secreting dozens of signaling proteins that regulate metabolism, inflammation, and cardiovascular risk. Among these, secreted frizzled-related protein 5 (SFRP5)¹¹ secreted frizzled-related protein 5 (SFRP5)
SFRP5 belongs to the secreted frizzled-related protein family, which are soluble decoy receptors for Wnt ligands. SFRP5 is produced predominantly by adipocytes and suppresses Wnt5a, a non-canonical Wnt ligand that drives macrophage activation and adipose inflammation stands out as a protective adipokine whose expression inversely tracks with metabolic health: lean individuals have more of it, obese individuals have less. rs6954668 is an intergenic variant in a regulatory region near the SFRP5 locus on chromosome 7 at position 1,656,051 (GRCh38). The A allele is strongly enriched in populations of African ancestry (~19% allele frequency) but is nearly absent in European (~0.06%), East Asian (0%), and South Asian (~0.06%) populations.

The Mechanism

SFRP5's protective role in metabolic disease runs through a specific molecular axis: Wnt5a → JNK → macrophage activation²² Wnt5a → JNK → macrophage activation
Wnt5a is a non-canonical Wnt ligand that signals through receptor tyrosine kinase-like orphan receptor (ROR2) and Frizzled receptors to activate the c-Jun N-terminal kinase (JNK) pathway, promoting macrophage inflammatory polarization and cytokine release. SFRP5 acts as a decoy receptor, binding Wnt5a extracellularly before it can engage its membrane receptors. When adipose tissue expands in obesity, adipocyte SFRP5 secretion falls while Wnt5a secretion rises — an inflammatory tipping point that promotes macrophage infiltration (characterized by [crown-like structures | Histological hallmarks of adipose tissue inflammation: clusters of macrophages surrounding dead or dying adipocytes, seen on H&E staining of adipose biopsies from obese individuals]), impairs insulin signaling, and contributes to hepatic steatosis through systemic cytokine spillover.

Ouchi et al. (2010)³³ Ouchi et al. (2010)
Ouchi N et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science, 2010 demonstrated in mice that Sfrp5 deficiency on a high-calorie diet produced severe glucose intolerance and hepatic fat accumulation, while adenoviral SFRP5 restoration reversed these effects — establishing SFRP5 as an endogenous metabolic protector, not merely a correlate of leanness. The suppression of Wnt5a/JNK signaling is the mechanistic core.

The rs6954668 variant maps to an intergenic region approximately 9.7 kb upstream of ELFN1 on chromosome 7. The population frequency pattern — common in sub-Saharan African populations, rare or absent in non-African groups — suggests this variant arose on an African haplotype and has not undergone significant positive or negative selection in other populations. The variant has no ClinVar annotation and no published GWAS associations. Its connection to SFRP5 biology, while plausible given the SFRP5 locus regulatory architecture, rests on the gene-level evidence rather than direct variant-phenotype studies.

The Evidence

At the gene level, the SFRP5/Wnt5a axis is well-characterized. Hu et al. (2013)⁴⁴ Hu et al. (2013)
Hu W et al. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab, 2013 demonstrated in 317 subjects that circulating SFRP5 was significantly lower in overweight/obese individuals compared to lean controls (P<0.01), and that liraglutide treatment raised SFRP5 levels — suggesting that therapeutic metabolic improvement partly works by restoring this adipokine axis.

Genetic evidence for SFRP5 variants and fat distribution comes from Van Camp et al. (2014)⁵⁵ Van Camp et al. (2014)
Van Camp JK et al. Common genetic variation in sFRP5 is associated with fat distribution in men. Endocrine, 2014, who genotyped 1,014 obese non-diabetic individuals and 606 lean controls and found that the minor allele of rs7072751 explained 1.8% of variance in total abdominal fat in obese men. No association was found in women, pointing to a sex-specific or sex-modified SFRP5 effect on adiposity.

In cardiovascular disease, Tong et al. (2020)⁶⁶ Tong et al. (2020)
Tong S et al. Expression of SFRP5/Wnt5a in human epicardial adipose tissue and coronary artery disease. Life Sciences, 2020 found that coronary artery disease patients had lower SFRP5 and higher Wnt5a in epicardial adipose tissue and serum (all P<0.05), with associations independent of conventional cardiovascular risk factors.

For rs6954668 specifically, no direct phenotypic association studies have been published. The evidence basis is the gene-level biology and the population frequency pattern. This places the variant at emerging evidence level: the pathway is established; the specific variant's functional contribution has not been directly studied.

Practical Actions

For the common GG genotype, no SFRP5-specific intervention applies. For individuals carrying one or two A alleles — predominantly those of African ancestry — the potential for altered SFRP5/Wnt5a balance in adipose tissue warrants monitoring adipose-related metabolic markers, particularly with weight gain. Because SFRP5 levels respond to metabolic state (liraglutide and metformin raise them; obesity lowers them), the most direct way to support the SFRP5 axis is to address the metabolic factors that suppress it: specifically, ectopic fat accumulation in visceral and hepatic depots.

The African-ancestry enrichment of the A allele means that population-stratified research will be critical to resolving this variant's true phenotypic impact. GWAS studies in African-ancestry cohorts are underrepresented relative to their potential to identify variants like this one, which are invisible in European-ancestry studies.

Interactions

SFRP5 belongs to a broader adipokine network. Low SFRP5 co-occurs with high leptin, high TNF-α, and high IL-6 in obesity, forming a pro-inflammatory adipokine profile. The Wnt5a/JNK axis that SFRP5 suppresses also modulates macrophage function relevant to atherosclerotic plaque stability. Compound effects with variants in genes encoding other adipokines (adiponectin ADIPOQ, leptin LEP) or Wnt pathway components are biologically plausible but unstudied for this specific variant.